Navigation Links
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
Date:2/25/2008

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a clinical-stage company engaged in the development of novel pharmaceutical therapies for the treatment of cancer and immunological conditions, announced that it has appointed Matthew Ferguson to the new position of Chief Financial Officer. Mr. Ferguson brings extensive experience arranging financing and managing rapid growth in both life sciences and technology companies.

"We are delighted to have Matt on board as a key member of the Proteolix management team," said Susan Molineaux, Ph.D., the Company's President and CEO. "His experience building teams and infrastructure in high-growth environments and securing financing in both the private and public markets will serve Proteolix well as we continue to advance our clinical and research programs."

Before joining Proteolix, Mr. Ferguson served as CFO at medical device maker FoxHollow Technologies, Inc. During his five-year tenure there, the company advanced its flagship technology for the treatment of peripheral arterial disease through development, FDA approval and commercial launch in the U.S. Mr. Ferguson led FoxHollow's 2004 initial public offering and played a significant role in the company's 2007 merger with ev3 Inc. Mr. Ferguson previously held a variety of financial management and business development positions at ChannelPoint, Inc. and Hewlett-Packard. Mr. Ferguson holds an M.B.A. from the University of California at Berkeley and M.S. and B.S. degrees in engineering from the University of Pennsylvania and Stanford University, respectively.

"The Proteolix opportunity is driven by an expert team, a large unmet clinical need and compelling early clinical results for carfilzomib," commented Mr. Ferguson. "I look forward to contributing my skills and experience towards our dual goals of improving the lives of patients and generating substantial returns for our shareholders."

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, and dedicated to discovering, developing and commercializing pharmaceutical therapies that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In Phase I clinical studies, the Company's lead product candidate, carfilzomib (PR-171), demonstrated single-agent activity in the treatment of relapsed and refractory multiple myeloma. Carfilzomib is currently in Phase II clinical studies to evaluate its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies. Proteolix is also developing a pipeline of next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For more information, please visit the Company's website at http://www.proteolix.com.

Contact information:

Matthew Ferguson

investors@proteolix.com

650-266-2600


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. Accident Fund Names General Agency Company its 2007 Agency of the Year
3. American Laser Centers Names Bill Van Huis as Chief Revenue Officer
4. Omron Healthcare Names New Chief Operating Officer Bob Kondraske
5. Birla Sun Life Insurance Names Quest Diagnostics its Exclusive Provider of Health Assessment Services in India
6. WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering
7. Wyeth Consumer Healthcare Names New Head of Global R&D
8. Spectragenics Names Rpr Marketing Communications Agency of Record
9. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
10. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
11. CTG Names William D. McGuire a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures ... will join America's leading engineers at the American Society of Safety Engineers Conference ... Congress Center. , Engineers, speakers and exhibitors from more than 40 countries ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, a ... event, Distributed: Health, to be held in Nashville, Tennessee on September 7, 2016. ... 24-hour Hackathon preceding the event will host teams from around the world, competing ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... a new corporate identity and website at its “Transforming Outcomes” User Conference in ... marketing enhancements reflect i2i’s ongoing success to set the market standard for meaningful ...
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... ... for the Surgery Center at Sentara Northern Virginia Medical Center located in Woodbridge, ... of the hospital’s surgical services into a single site. , The new 2 ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... New York , May 23, 2016 ... market report titled, " Exocrine Pancreatic Insufficiency Market - ... 2013 - 2023 ." According to the report, the ... a CAGR of 8.3% from 2015 to 2023 to ... insufficiency (EPI) is a condition characterized by the deficiency ...
Breaking Medicine Technology: